{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib","item":"https:\/\/www.regionalcancercare.org\/trials\/phase-2-randomized-study-of-osimertinib-versus-osimertinib-plus-chemotherapy-for-patients-with-metastatic-egfr-mutant-lung-cancers-that-have-detectable-egfr-mutant-cfdna-in-plasma-after-initiation-of\/#breadcrumbitem"}]}